O	0	3	The	The	DT	B-NP
O	4	14	modulation	modulation	NN	I-NP
O	15	17	of	of	IN	B-PP
B-Cell	18	26	platelet	platelet	NN	B-NP
O	27	30	and	and	CC	O
B-Cell	31	42	endothelial	endothelial	JJ	B-NP
I-Cell	43	47	cell	cell	NN	I-NP
O	48	56	adhesion	adhesion	NN	I-NP
O	57	59	to	to	TO	B-PP
B-Multi-tissue_structure	60	68	vascular	vascular	JJ	B-NP
I-Multi-tissue_structure	69	74	graft	graft	NN	I-NP
O	75	84	materials	material	NNS	I-NP
O	85	87	by	by	IN	B-PP
O	88	96	perlecan	perlecan	NN	B-NP
O	96	97	.	.	.	O

O	98	108	Controlled	Control	VBN	B-VP
O	109	112	neo	neo	AFX	O
O	112	113	-	-	HYPH	O
O	113	131	endothelialisation	endothelialisation	NN	B-NP
O	132	134	is	be	VBZ	B-VP
O	135	143	critical	critical	JJ	B-ADJP
O	144	146	to	to	TO	B-PP
O	147	150	the	the	DT	B-NP
O	151	158	patency	patency	NN	I-NP
O	159	161	of	of	IN	B-PP
O	162	167	small	small	JJ	B-NP
O	168	176	diameter	diameter	NN	I-NP
B-Multi-tissue_structure	177	185	vascular	vascular	JJ	I-NP
I-Multi-tissue_structure	186	192	grafts	graft	NNS	I-NP
O	192	193	.	.	.	O

O	194	212	Endothelialisation	Endothelialisation	NN	B-NP
O	213	216	and	and	CC	I-NP
B-Cell	217	225	platelet	platelet	NN	I-NP
O	226	234	adhesion	adhesion	NN	I-NP
O	235	237	to	to	TO	B-PP
O	238	246	purified	purify	VBN	B-NP
B-Cell	247	258	endothelial	endothelial	JJ	I-NP
I-Cell	259	263	cell	cell	NN	I-NP
O	263	264	-	-	HYPH	B-NP
O	264	271	derived	derive	VBN	I-NP
O	272	280	perlecan	perlecan	NN	I-NP
O	280	281	,	,	,	O
O	282	285	the	the	DT	B-NP
O	286	291	major	major	JJ	I-NP
O	292	299	heparan	heparan	NN	I-NP
O	300	307	sulfate	sulfate	NN	I-NP
O	308	309	(	(	(	O
O	309	311	HS	HS	NN	B-NP
O	311	312	)	)	)	O
O	313	325	proteoglycan	proteoglycan	NN	B-NP
O	326	328	in	in	IN	B-PP
B-Cellular_component	329	337	basement	basement	NN	B-NP
I-Cellular_component	338	347	membranes	membrane	NNS	I-NP
O	347	348	,	,	,	O
O	349	353	were	be	VBD	B-VP
O	354	366	investigated	investigate	VBN	I-VP
O	367	372	using	use	VBG	B-VP
O	373	375	in	in	FW	B-ADVP
O	376	380	vivo	vivo	FW	I-ADVP
O	381	384	and	and	CC	O
O	385	387	in	in	FW	B-NP
O	388	393	vitro	vitro	FW	I-NP
O	394	400	assays	assay	NNS	I-NP
O	400	401	.	.	.	O

O	402	410	Expanded	Expand	VBN	B-NP
O	411	434	polytetrafluoroethylene	polytetrafluoroethylene	NN	I-NP
O	435	436	(	(	(	O
O	436	441	ePTFE	ePTFE	NN	B-NP
O	441	442	)	)	)	O
B-Multi-tissue_structure	443	451	vascular	vascular	JJ	B-NP
I-Multi-tissue_structure	452	458	grafts	graft	NNS	I-NP
O	459	463	were	be	VBD	B-VP
O	464	470	coated	coat	VBN	I-VP
O	471	475	with	with	IN	B-PP
O	476	484	perlecan	perlecan	NN	B-NP
O	485	488	and	and	CC	O
O	489	495	tested	test	VBN	B-VP
O	496	498	in	in	IN	B-PP
O	499	501	an	an	DT	B-NP
O	502	507	ovine	ovine	JJ	I-NP
B-Multi-tissue_structure	508	515	carotid	carotid	NN	I-NP
O	516	529	interposition	interposition	NN	I-NP
O	530	535	model	model	NN	I-NP
O	536	539	for	for	IN	B-PP
O	540	541	a	a	DT	B-NP
O	542	548	period	period	NN	I-NP
O	549	551	of	of	IN	B-PP
O	552	553	6	6	CD	B-NP
O	554	559	weeks	week	NNS	I-NP
O	560	563	and	and	CC	O
O	564	572	assessed	assess	VBN	B-VP
O	573	578	using	use	VBG	B-VP
O	579	584	light	light	NN	B-NP
O	585	588	and	and	CC	I-NP
O	589	597	scanning	scanning	NN	I-NP
O	598	608	microscopy	microscopy	NN	I-NP
O	608	609	.	.	.	O

O	610	618	Enhanced	Enhance	VBN	B-NP
B-Cell	619	630	endothelial	endothelial	JJ	I-NP
I-Cell	631	635	cell	cell	NN	I-NP
O	636	642	growth	growth	NN	I-NP
O	643	646	and	and	CC	O
O	647	654	reduced	reduce	VBD	B-VP
B-Cell	655	663	platelet	platelet	NN	B-NP
O	664	672	adhesion	adhesion	NN	I-NP
O	673	677	were	be	VBD	B-VP
O	678	686	observed	observe	VBN	I-VP
O	687	689	on	on	IN	B-PP
O	690	693	the	the	DT	B-NP
O	694	702	perlecan	perlecan	NN	I-NP
O	703	709	coated	coat	VBD	B-VP
B-Multi-tissue_structure	710	716	grafts	graft	NNS	B-NP
O	717	721	when	when	WRB	B-ADVP
O	722	730	compared	compare	VBN	B-VP
O	731	733	to	to	TO	B-PP
O	734	742	uncoated	uncoated	JJ	B-NP
O	743	751	controls	control	NNS	I-NP
O	752	761	implanted	implant	VBN	B-VP
O	762	764	in	in	IN	B-PP
O	765	768	the	the	DT	B-NP
O	769	773	same	same	JJ	I-NP
O	774	779	sheep	sheep	NN	I-NP
O	780	781	(	(	(	O
O	781	782	n	n	NN	B-NP
O	782	783	=	=	SYM	B-VP
O	783	784	5	5	CD	B-NP
O	784	785	)	)	)	O
O	785	786	.	.	.	O

O	787	795	Perlecan	Perlecan	NN	B-NP
O	796	799	was	be	VBD	B-VP
O	800	804	also	also	RB	I-VP
O	805	810	found	find	VBN	I-VP
O	811	813	to	to	TO	I-VP
O	814	823	stimulate	stimulate	VB	I-VP
B-Cell	824	835	endothelial	endothelial	JJ	B-NP
I-Cell	836	840	cell	cell	NN	I-NP
O	841	854	proliferation	proliferation	NN	I-NP
O	855	857	in	in	FW	B-ADVP
O	858	863	vitro	vitro	FW	I-ADVP
O	864	868	over	over	IN	B-PP
O	869	870	a	a	DT	B-NP
O	871	877	period	period	NN	I-NP
O	878	880	of	of	IN	B-PP
O	881	882	6	6	CD	B-NP
O	883	887	days	day	NNS	I-NP
O	888	890	in	in	IN	B-PP
O	891	894	the	the	DT	B-NP
O	895	903	presence	presence	NN	I-NP
O	904	906	of	of	IN	B-PP
B-Organism_substance	907	913	plasma	plasma	NN	B-NP
O	914	922	proteins	protein	NNS	I-NP
O	923	926	and	and	CC	O
O	927	939	fibroblastic	fibroblastic	JJ	B-NP
O	940	946	growth	growth	NN	I-NP
O	947	953	factor	factor	NN	I-NP
O	954	955	2	2	CD	I-NP
O	956	957	(	(	(	O
O	957	960	FGF	FGF	NN	B-NP
O	960	961	-	-	HYPH	O
O	961	962	2	2	CD	B-NP
O	962	963	)	)	)	O
O	963	964	,	,	,	O
O	965	972	however	however	RB	B-ADVP
O	973	975	in	in	IN	B-PP
O	976	979	the	the	DT	B-NP
O	980	987	absence	absence	NN	I-NP
O	988	990	of	of	IN	B-PP
O	991	994	FGF	FGF	NN	B-NP
O	994	995	-	-	HYPH	B-NP
O	995	996	2	2	CD	I-NP
B-Cell	997	1008	endothelial	endothelial	JJ	I-NP
I-Cell	1009	1013	cell	cell	NN	I-NP
O	1014	1020	growth	growth	NN	I-NP
O	1021	1026	could	could	MD	B-VP
O	1027	1030	not	not	RB	I-VP
O	1031	1033	be	be	VB	I-VP
O	1034	1044	maintained	maintain	VBN	I-VP
O	1045	1051	during	during	IN	B-PP
O	1052	1056	this	this	DT	B-NP
O	1057	1063	period	period	NN	I-NP
O	1063	1064	.	.	.	O

O	1065	1073	Perlecan	Perlecan	NN	B-NP
O	1074	1077	was	be	VBD	B-VP
O	1078	1083	found	find	VBN	I-VP
O	1084	1086	to	to	TO	I-VP
O	1087	1089	be	be	VB	I-VP
O	1090	1094	anti	anti	AFX	B-ADJP
O	1094	1095	-	-	HYPH	I-ADJP
O	1095	1103	adhesive	adhesive	JJ	B-ADJP
O	1104	1107	for	for	IN	B-PP
B-Cell	1108	1117	platelets	platelet	NNS	B-NP
O	1117	1118	,	,	,	O
O	1119	1126	however	however	RB	B-ADVP
O	1127	1132	after	after	IN	B-PP
O	1133	1140	removal	removal	NN	B-NP
O	1141	1143	of	of	IN	B-PP
O	1144	1147	the	the	DT	B-NP
O	1148	1150	HS	HS	NN	I-NP
O	1151	1157	chains	chain	NNS	I-NP
O	1158	1166	attached	attach	VBN	B-VP
O	1167	1169	to	to	TO	B-PP
O	1170	1178	perlecan	perlecan	NN	B-NP
O	1178	1179	,	,	,	I-NP
B-Cell	1180	1188	platelet	platelet	NN	I-NP
O	1189	1197	adhesion	adhesion	NN	I-NP
O	1198	1201	and	and	CC	I-NP
O	1202	1213	aggregation	aggregation	NN	I-NP
O	1214	1218	were	be	VBD	B-VP
O	1219	1228	supported	support	VBN	I-VP
O	1228	1229	.	.	.	O

O	1230	1235	These	These	DT	B-NP
O	1236	1243	results	result	NNS	I-NP
O	1244	1251	suggest	suggest	VBP	B-VP
O	1252	1253	a	a	DT	B-NP
O	1254	1258	role	role	NN	I-NP
O	1259	1262	for	for	IN	B-PP
O	1263	1265	HS	HS	NN	B-NP
O	1266	1272	chains	chain	NNS	I-NP
O	1273	1275	of	of	IN	B-PP
O	1276	1284	perlecan	perlecan	NN	B-NP
O	1285	1287	in	in	IN	B-PP
O	1288	1297	improving	improve	VBG	B-VP
B-Multi-tissue_structure	1298	1303	graft	graft	NN	B-NP
O	1304	1311	patency	patency	NN	I-NP
O	1312	1314	by	by	IN	B-PP
O	1315	1326	selectively	selectively	RB	B-ADVP
O	1327	1336	promoting	promote	VBG	B-VP
B-Cell	1337	1348	endothelial	endothelial	JJ	B-NP
I-Cell	1349	1353	cell	cell	NN	I-NP
O	1354	1367	proliferation	proliferation	NN	I-NP
O	1368	1373	while	while	IN	B-SBAR
O	1374	1384	modulating	modulate	VBG	B-VP
B-Cell	1385	1393	platelet	platelet	NN	B-NP
O	1394	1402	adhesion	adhesion	NN	I-NP
O	1402	1403	.	.	.	O

